ONC
BeOne Medicines AG · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.1% ·
share flow +0.2% ·
net new positions +10.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | -6 | 22.51M | $6.43B | +4 | −10 |
| Q1 2026 | 100 | +2 | 21.59M | $6.42B | +8 | −6 |
| Q4 2025 | 97 | +2 | 20.58M | $6.25B | +2 | — |
| Q3 2025 | 14 | -1 | 11.95M | $4.07B | +1 | −2 |
| Q2 2025 | 12 | -4 | 11.51M | $2.79B | +1 | −5 |
| Q1 2025 | 14 | +4 | 13.65M | $3.71B | +4 | — |
| Q4 2024 | 10 | +1 | 12.37M | $2.28B | +1 | — |
| Q3 2024 | 9 | +1 | 12.34M | $2.77B | +1 | — |
| Q2 2024 | 8 | — | 11.43M | $1.63B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 5.10M | +2.5% | $941.82M | 0.7% | ▲ Add | 3 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 3.67M | -0.9% | $678.11M | 0.5% | ▼ Trim | 3 | SEC ↗ ×4 |
| 3 | T. Rowe Price ✦ | 2.94M | +8.8% | $542.52M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 317.11K | +574.2% | $58.57M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 145.76K | +155.2% | $26.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 100.01K | -6.0% | $18.47M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 38.25K | +1.3% | $7.07M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 31.16K | -32.2% | $5.76M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 9 | Point72 Asset Management ✦ | 25.17K | -96.2% | $4.65M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Bridgewater Associates ✦ | 1.61K | New | $297,383 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $297,383 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 278 holders, 34.74M shares, $10.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.11K sh · $418,125
Director · 738 sh · $271,012
Director · 14.53K sh · $5.32M
Director · 2.05K sh · $748,891
Director · 3.42K sh · $1.24M
Director · 3.50K sh · $1.27M
Director · 4.24K sh · $1.54M
Director · 2.24K sh · $809,120
Director · 40 sh · $14,366
Director · 120 sh · $43,045
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.8% of class · View original SEC filing ↗
8.0% of class · View original SEC filing ↗